Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877628 | 0.88 | SLC9A1 (0.41) | SLC9A1 | |
| SCHEMBL907705 | 0.85 | SLC9A1 (0.36) | SCN9ASLC9A1MAP3K12 | |
| SCHEMBL908196 | 0.85 | MAP3K12 (0.40) | MTORSLC9A1MAP3K12 | |
| SCHEMBL3877165 | 0.84 | SLC9A1 (0.41) | SLC9A1MAP3K12 | |
| SCHEMBL908028 | 0.83 | HRH4 (0.36) | SLC9A1MAP3K12 | |
| SCHEMBL3875754 | 0.82 | TRPV1 (0.37) | SLC9A1MAP3K12CHRM4 | |
| SCHEMBL4257261 | 0.81 | MAP3K12 (0.39) | SLC9A1MAP3K12AXL | |
| SCHEMBL908447 | 0.80 | CHRNB1 (0.36) | SLC9A1MAP3K12AXL | |
| SCHEMBL3880083 | 0.79 | SLC9A1 (0.45) | SLC9A1MAP3K12 | |
| SCHEMBL907898 | 0.79 | MPL (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| EP-1644358-A2 | BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007648-A2 | BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | SCN9A 3553/4885MTOR 2949/4885SLC9A1 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.